Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1258826.RAjLDc1Cimu-VvTnuRwxBn-sw0vnSfrKik-yprs5OoFqU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1258826.RAjLDc1Cimu-VvTnuRwxBn-sw0vnSfrKik-yprs5OoFqU130_assertion type Assertion NP1258826.RAjLDc1Cimu-VvTnuRwxBn-sw0vnSfrKik-yprs5OoFqU130_head.
- NP1258826.RAjLDc1Cimu-VvTnuRwxBn-sw0vnSfrKik-yprs5OoFqU130_assertion description "[Aromatase inhibitor (AI) treatment is first-line systemic treatment for the majority of postmenopausal breast cancer patients with estrogen receptor (ER)-positive primary tumor.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1258826.RAjLDc1Cimu-VvTnuRwxBn-sw0vnSfrKik-yprs5OoFqU130_provenance.
- NP1258826.RAjLDc1Cimu-VvTnuRwxBn-sw0vnSfrKik-yprs5OoFqU130_assertion evidence source_evidence_literature NP1258826.RAjLDc1Cimu-VvTnuRwxBn-sw0vnSfrKik-yprs5OoFqU130_provenance.
- NP1258826.RAjLDc1Cimu-VvTnuRwxBn-sw0vnSfrKik-yprs5OoFqU130_assertion SIO_000772 25625755 NP1258826.RAjLDc1Cimu-VvTnuRwxBn-sw0vnSfrKik-yprs5OoFqU130_provenance.
- NP1258826.RAjLDc1Cimu-VvTnuRwxBn-sw0vnSfrKik-yprs5OoFqU130_assertion wasDerivedFrom befree-2016 NP1258826.RAjLDc1Cimu-VvTnuRwxBn-sw0vnSfrKik-yprs5OoFqU130_provenance.
- NP1258826.RAjLDc1Cimu-VvTnuRwxBn-sw0vnSfrKik-yprs5OoFqU130_assertion wasGeneratedBy ECO_0000203 NP1258826.RAjLDc1Cimu-VvTnuRwxBn-sw0vnSfrKik-yprs5OoFqU130_provenance.